Resolian is a leading global Contract Research Organization (CRO) providing specialized services in GxP and non-regulated bioanalysis, drug metabolism/pharmacokinetic (DMPK), and GMP CMC analytical and materials science. Comprised of the former Alliance Pharma Inc, Drug Development Solutions Ltd, and Denali Medpharma labs and powered by a team of more than 500 experts across the US, UK, Australia, and China, Resolian supports pharma and biotech companies’ programs throughout the entire drug development continuum. Resolian’s specialized solutions include small and large molecule LC-MS/MS bioanalysis, PK immunoassays for large molecules, immunogenicity, biomarkers, cell-based assays, and drug metabolism. These solutions are delivered through Resolian’s dedicated global laboratories, equipped with state-of-the-art technology and ready to meet client needs for preclinical studies as well as regional or global clinical programs. We are committed to delivering high-quality results and ensuring compliance with regulatory requirements. Its team of experts works closely with clients to develop customized solutions for each specific program requirements. A trusted partner for pharmaceutical and biotech companies seeking specialized support in drug development, Resolian’s extensive expertise, advanced technology, and commitment to quality combine to fully deliver for companies of all sizes and at any stage of the drug development process.
Propharma
At ProPharma, we help pharmaceutical, biotechnology, and medical device companies bring life-changing therapies to market. From early development through clinical, regulatory approval, and commercialization, we provide expert guidance to navigate complex challenges and accelerate success. Our mission is simple – improving patient health and safety by delivering the highest quality regulatory, compliance, clinical research, pharmacovigilance, and medical information services throughout the entire product lifecycle. | For over 25 years, ProPharma has partnered with biotech, pharmaceutical, and medical device organizations to bring groundbreaking therapies to market. Offering a fully customizable, end-to-end suite of services, we empower our clients to overcome regulatory complexities and deliver life-changing therapies to patients worldwide. At ProPharma, we help pharmaceutical, biotechnology, and medical device companies bring life-changing therapies to market. From early development through clinical, regulatory approval, and commercialization, we provide expert guidance to navigate complex challenges and accelerate success. Our mission is simple – improving patient health and safety by delivering the highest quality regulatory, compliance, clinical research, pharmacovigilance, and medical information services throughout the entire product lifecycle.
ProJect Pharmaceutics (PJP)
PJP is the go-to specialist in formulation and process development across complex biologics, bioconjugates, and other therapeutic modalities. Our development agility spans liquid, frozen, and lyo formats in vials, cartridges, or pre-filled syringes and in-step or independent from your chosen manufacturer. Let’s solve your formulation and process challenges together.
Profil GmbH
Profil is the world’s leading CRO in metabolic research. As a full-service provider, we conduct early phase clinical trials within the indications of obesity, (pre)diabetes, and diabetes complications. We offer an unrivaled combination of science and professional conduct. This unique combination allows us to design and carry out best-in-class clinical trials for our clients. Our in-house scientific expertise covers pharmacology, obesity and prediabetes, nutritional sciences, cardiometbolic research, hepatology, endocrinology, the entire spectrum of diabetes complications, cell and molecular biology as well as metabolic monitoring and medical technology. One of our core technologies is the hyperinsulinemic euglycemic clamp, used to address action profiles of insulin and insulin analogues, beta cell function and insulin sensitivity. To address human metabolic pathways glucose clamp studies are combined with isotope dilution techniques and tissue biopsies. To be able to offer the best services for any glucose clamping setup, we have developed ClampArt, the next generation of glucose clamping. By owning a continuously updated database with entries of more than 30.000 well characterized individuals (healthy, healthy at-risk, type 1 and type 2 diabetes), we can recruit even the most complex clinical trials. We have a fully GMP certified pharmacy and in-house clinics with 60 beds and holds expertise in Data Management & Statistics and Regulatory Affairs.
Preclina Inc
Immune Specialists’ Research Service CRO: [ Booth # 4158] Preclina is a non-clinical CRO with a fully-integrated drug discovery platform specializing in Immunology. We offer a portfolio of models for efficacy pharmacology studies in autoimmunity, immuno-oncology, and transplantation immunology. Our platforms include humanized mouse models recapitulating autoimmune diseases and humanized tumor xenografts, enabling preclinical evaluation of biologics, cell therapies, and novel immunotherapies. With over 20 years of expertise in immunology, immunotoxicology, and bioanalysis, Preclina delivers integrated, customizable solutions with a focus on scientific rigor, speed, and cost-efficiency. Our advanced approaches help accelerate drug discovery and reduce development risk. We serve as a “Bridging Specialist” connecting non-clinical and clinical stages, supporting biotech and pharma partners in optimizing pipelines and making faster, smarter decisions in immunology drug development. Meet us at Booth # 4158. Our Preclinical Services: ● Comprehensive in vivo efficacy pharmacology services utilizing well-established autoimmune and inflammatory disease models, augmented by pioneering, technically advanced humanized autoimmune disease model platforms ● Humanized mouse models for immunotherapeutic development and pathogenesis research in oncology and transplantation immunology fields ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and the fastest results [PreVIVO™ Platform] Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Autoimmune Specialists’ Research Service CRO: Preclina is a non-clinical CRO specialized in autoimune and inflammatory disorders, providing the utmost quality services for novel drug development at the lightning speed, highest quality, and reasonable cost. In the global market of immune disease therapeutics, which shows explosive growth, Preclina Inc is a leading company that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. [Our preclinical services] ● In vivo efficacy pharmacology using disease models recapitulating autoimmune and inflammatory disorders ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and fastest track results (Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA) ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Preclina is a global leading non-clinical CRO that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We’re strengthening our leadership in immunological research by broadening our portfolio with sophisticated humanized mouse models, specifically optimized for oncology drug development. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. Our preclinical services: ● In vivo efficacy pharmacology using disease models recapitulating autoimmune and inflammatory disorders ● Humanized mouse models for immunotherapeutic development and pathogenesis research in oncology and transplantation immunology fields ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and fastest track results Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Immune Specialists’ Research Service CRO: [ Booth #3816] Predict Your Clinical Success with “World’s First” Humanized Models Preclina is a “Bridging Specialist” that eliminates the uncertainty of the translational gap. We provide the high-fidelity data needed to turn early-stage assets into clinical success stories. 1. Proven Excellence in Immunology – Expertise: Over 20 years specializing in immunology, immunotoxicology, and bioanalysis. – Track Record: Contributed to $600M+ global license-out deals. – Reliability: Supported multiple assets achieving final FDA approval. 2. The PreHu™ Advantage: Unrivaled Predictive Power Gain an exclusive competitive edge with our quartet of World’s First & Pioneering commercialized humanized disease models: – World’s First Lineup: Our peer-reviewed models for Psoriasis, Atopic Dermatitis, BILF, and DSS-induced Colitis are the first of their kind commercialized globally. – Peer-Reviewed Authority: All four models are published in leading journals, ensuring high reproducibility and scientific rigor. – Translational Relevance: These platforms recapitulate the human immune system in a patient-like environment to accurately validate biologics and cell therapies. 3. Operational Speed & Strategy PreVIVO™ Platform: Access modular services (PrePsora, PreBILFi, PreNASHa, etc.) for the fastest, most consistent data. – Risk Reduction: Integrated services encompass lead selection to candidate development, dramatically reducing late-stage failure rates. – Strategic Grant: The PreTrial™ Program offers exclusive grant support to qualified companies to bridge the “PoC Hurdle” and boost asset valuation. Consult with our Global Business Development team to de-risk your pipeline today [ Humanized Mouse Model Platform (PreHu™) ] 1. Humanized CDX/PDX (Patient-Derived Xenograft)-Based Efficacy Services : This platform implants tumor cells/tissues into humanized mice for bio-pharmaceutical efficacy evaluations in a patient-like environment, crucial for immuno-oncology and cell therapy assessments. – Humanized CDX/PDX Model – Humanized PBMC/HSc Model – GvHD Model 2. Humanized Autoimmune Disease / Fibrosis Mouse Model : We have pioneered the world’s first service platform with four or more humanized autoimmune disease models, providing essential preclinical services for the development of biopharmaceuticals, such as antibody drugs and cell therapies. – Humanized Ulcerative Colitis (UC) Model – Humanized Pulmonary Fibrosis (IPF) Model – Humanized Psoriasis Model – Humanized Atopic Dermatitis Model [Efficacy Evaluation Pharmacology Services (PreVIVO™) ] 1. Arthritis Research Service: Preclina’s service not only includes all essential models for evaluating the efficacy in the development of therapeutic agents for rheumatoid arthritis but also provides the key model for osteoarthritis – CIA Model / CAIA Model / ACLT Model 2. Fibrosis Research Service: With extensive expertise in immunology and fibrosis research, we have the flexibility to lead drug efficacy assessment projects with in-depth insights, maximizing the potential for success in new drug development. – BILF Model / BISF Model / MASH Model 3. Atopic Dermatitis & Psoriasis Research Service: Preclina provides specialized inflammatory skin disease models to support preclinical and mechanistic research in dermatology. These models include psoriasis, atopic dermatitis, and hypersensitivity disorders, enabling precise evaluation through mRNA analysis, protein assays, histopathology, and cellular assessments. With internationally standardized read-outs and customized research services, our models enhance the success rate of new drug development. – Imiquimod-Induced Psoriasis / IL-23-Induced Psoriasis Models – Oxazolone-Induced AD / House Dust Mite-Induced AD Models 4. Inflammatory Bowel Disease Research Service : Preclina provides specialized models for inflammatory bowel disease (IBD) research. These models include the ulcerative colitis model (Dextran Sodium Sulfate, DSS-induced colitis) and the Crohn’s disease model (Dinitrobenzene Sulfonic Acid, DNBS-induced colitis). These models accurately replicate disease onset and progression, enabling comprehensive disease activity index (DAI) assessments, histopathologic evaluations, biomarker analyses, and toxicity assessments. – DSS-Induced Colitis / DNBS-Induced Colitis Models 5. Lupus Research Service: Preclina provides key animal models for lupus and Sjogren syndrome research. For lupus, it supports the development of new drugs targeting B lymphocytes, cell surface molecules, signaling pathway proteins, and regulatory cytokines. It also offers a mouse model for Sjogren syndrome. – MRL/lpr Lupus Model / NZBW F1 Lupus Model 6. Neuroscience Research Service: Preclina provides a specialized EAE (Experimental Autoimmune Encephalomyelitis) animal model to support preclinical research and mechanistic studies on multiple sclerosis (MS). In particular, the MOG-induced EAE mouse model serves as a standard model that closely resembles the inflammatory pathogenesis of MS driven by autoimmune mechanisms, making it widely utilized for evaluating disease progression and treatment responses. – MOG EAE Model / PLP EAE Model [Non-GLP Toxicology service & ADME-PK ] Customized PK/ADME-Tox evaluation services for dramatically enhancing the potential for successful drug development.
PreciGenome LLC
PreciGenome LLC, located in the heart of Silicon Valley in San Jose, California, is a leading innovator in developing state-of-the-art Lipid Nanoparticle (LNP) synthesis instruments and associated reagents, empowering researchers and pharmaceutical developers in their drug delivery endeavors. Our advanced microfluidic platforms enable precise and efficient LNP production, crucial for mRNA therapeutics and vaccine development. We offer comprehensive solutions that include both cutting-edge instrumentation, high-quality reagents and services, ensuring seamless integration and optimal results for our clients. At PreciGenome, we understand the critical nature of LNP formulation in modern drug delivery systems. Our technology delivers consistent particle size distribution and exceptional encapsulation efficiency, meeting the exacting standards required in pharmaceutical development. Whether you’re conducting early-stage research or scaling up for production, our systems provide the reliability and reproducibility essential for success in LNP-based therapeutics.
Phastar
Phastar is an award-winning biometrics and data science CRO, trusted by pharma, biotech, and medical device companies worldwide. With a global team of data specialists, we bring expertise, precision, and pace to every trial—because behind every data point is a patient waiting for treatment. We don’t just deliver on-time high quality data; we partner with you to turn complexity into clarity. Leveraging best-in-class technology, AI-enhanced analytics, advanced statistical methods, and deep therapeutic expertise, we accelerate regulatory approvals, ensure compliance with global standards and seamlessly mitigate risk. Our proven track record in transforming complex data into clear, actionable intelligence enables you to accelerate drug development. With scalable, tailored solutions, we expedite trials—bringing life-changing therapies to patients faster.
Phase Clinical Services
Your complete resource for oncology clinical trials and biospecimens | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies. Our clients are pharma and biotech companies from startup to the top-ten level, assay developers, high-end academic institutions, and the U.S. government. We maintain an FDA-registered cell isolation lab in Milwaukee and an in-house pathology service. | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies.
PharSafer
Founded in 2003 by Dr Graeme Ladds, PharSafer® is a specialist Contract Research Organisation (CRO) in Global Clinical and Post Marketing Drug Safety, and Medical Services, with a wealth of experience in Pharmacovigilance, Auditing and Medical Affairs – and the various, numerous and extensive legal safety/medical obligations for licence holders to comply with – as well as Regulatory Strategy for the best methods for obtaining scientific advice concerning licence submissions and approvals. Together with our sister company which focuses on Training: SaPhar, PharSafer® continuously seeks new and innovative ways to provide added value for our global clients – going above and beyond expectations and optimising processes and procedures involved with clinical and post marketing drug safety and licencing approach. Our ability to offer first-class services in Pharmacovigilance, Regulatory Affairs, Training, Auditing, Medical Affairs and IT Informatics means that, for many clients, we operate as their Pharmacovigilance and Medical Departments – guiding them through the labyrinth of drug safety and medical legislation, all in the interests of ensuring patient safety and client compliance. We love what we do. We love finding solutions. Quite simply, we are by far… Your leading partner in Drug Safety. | PharSafer is a Global CRO specialising in Clinical & Post Marketing Pharmacovigilance; Medical Affairs; Training; Auditing; IT Informatics and Regulatory Intelligence. PharSafer have been operating for the last 23 years growing annually and helping take Companies from their clinical to post-marketing phases and many clients have been with us over 10 years now. PharSafer have attended over 100 inspections on behalf of clients to aid their compliance and ensure Regulatory Authorities are satisfied with the activities being performed. PharSafer are also an innovative Company designing validated and automated systems to provide cost-effective solutions for clients and ensure Regulatory compliant systems. Our client base is truly global being in all continents and for clients that have drugs; devices; vaccines; biologics; advanced therapies; biosimilars; herbal and cosmetics. Our Team within the Company are very experienced (many with over 15 years experience) aided by our sister training Company (SaPhar) to provide new updates for clients on country specific regulations with regular monthly contacts and comments going to all clients. We would be happy to engage with you and talk about product development; product expansions into new countries; product launches and perform all of the activities mentioned above. Please review of website and we look forward to engaging with you personally.